Medical Editor: John P. Cunha, DO, FACOEP
What Is Corlopam?
Corlopam (fenoldopam mesylate) Injection is a dopamine receptor agonist (vasodilator) used for in-hospital, short-term (up to 48 hours) management of severe high blood pressure (hypertension) when rapid, but quickly reversible, emergency reduction of blood pressure is indicated. Corlopam is available in generic form.
What Are Side Effects of Corlopam?
Common side effects of Corlopam include headache, flushing (warmth, redness, or tingly feeling, particularly in the face and neck), nausea, low blood pressure (hypotension), fast heartbeat, and low blood potassium.
Dosage for Corlopam?
The drug dose rate of Corlopam is individualized for each patient according to body weight and according to the desired rapidity and extent of pharmacodynamic effect.
What Drugs, Substances, or Supplements Interact with Corlopam?
Corlopam may interact with other drugs. Tell your doctor all medications and supplements you use.
Corlopam During Pregnancy and Breastfeeding
During pregnancy, Corlopam should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Corlopam (fenoldopam mesylate) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The most common reactions associated with fenoldopam use are headache, cutaneous dilation (flushing), nausea, and hypotension, each reported in more than 5% of patients.
Adverse reactions occurring more than once in any dosing group (once if potentially important or plausibly drug-related) in the fixed-dose constant-infusion studies are presented in Table 5. There was no clear dose relationship, except possibly for headache, nausea, flushing.
Table 5: Adverse reactions in fixed-dose studies
occurring in > 5% of subjects on fenoldopam
(n = 7)
(n = 125)
|Headache||1 (14%)||30 (24%)|
|Injection site reaction||0||9 (7%)|
|Electrocardiogram T wave inversion||0||7 (6%)|
The following additional adverse reactions were observed more frequently in patients treated with fenoldopam
Incidence 0.5% to 5%
Metabolism and Nutrition Disorders — Hypokalaemia
Psychiatric Disorders — Nervousness/Anxiety, insomnia
Nervous System Disorders — Dizziness
Gastrointestinal Disorders — Abdominal pain
Skin and Subcutaneous Tissue Disorders — Hyperhidrosis
Musculoskeletal and Connective Tissue Disorders —Muscle spasms
Renal and Urinary Disorders — Oliguria
General Disorders and Administration Site Conditions —Chest pain, pyrexia
Investigations — Blood urea increased, blood creatinine increased, blood glucose increased, transaminases increased, blood lactate dehydrogenase increased
The following adverse reactions have been identified during post approval use of Corlopam. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Voluntary reports of adverse reactions temporally associated with Corlopam that have been received since market introduction and that may have no causal relationship with the drug include the following:
Cardiac Disorders — Cardiogenic shock
Vascular Disorders — Hypotension
Gastrointestinal Disorders — Abdominal distension
Investigations — Electrocardiogram ST segment depression, oxygen saturation decreased
Read the entire FDA prescribing information for Corlopam (Fenoldopam Mesylate Injection)